Conclusion
There is a clearly defined pathway to developing and evaluating complex interventions; however, significant variation exists in the extent to which the pathway is followed. Within the pathway, there are inconsistencies of interpretation, for example the definition of an acceptable primary outcome. There is a need for the deprescribing community to address the inconsistencies and then follow the agreed pathway from defining the target deprescribing behaviour through to evaluating intervention fidelity alongside effectiveness.